Fate Therapeutics Inc (FATE)

Dec 19, 2024

Critical Survey: Fate Therapeutics (NASDAQ:FATE) versus HilleVax (NASDAQ:HLVX) - Defense World

Dec 19, 2024

Dec 18, 2024

Fmr LLC Buys 46,892 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 18, 2024

Dec 17, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Significant Growth in Short Interest - MarketBeat

Dec 17, 2024

Dec 16, 2024

FATE LAWSUIT ALERT: Levi & Korsinsky Notifies Fate Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Marketscreener.com

Dec 16, 2024

Dec 15, 2024

Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks - Investing.com

Dec 15, 2024

Dec 15, 2024

Fate Therapeutics' SWOT analysis: cell therapy stock shows promise amid risks By Investing.com - Investing.com South Africa

Dec 15, 2024

Dec 13, 2024

BNP Paribas Financial Markets Raises Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Dec 13, 2024

Dec 12, 2024

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Dec 12, 2024

Dec 12, 2024

FATE stock touches 52-week low at $1.96 amid market challenges - Investing.com

Dec 12, 2024

Dec 12, 2024

FATE stock touches 52-week low at $1.96 amid market challenges By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 09, 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus - The Manila Times

Dec 09, 2024

Dec 09, 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for - EIN News

Dec 09, 2024

Dec 09, 2024

Fate Therapeutics' Off-the-Shelf CAR T Shows Breakthrough Results in Lupus TreatmentPhase 1 Data - StockTitan

Dec 09, 2024

Dec 03, 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Dec 03, 2024

Dec 03, 2024

Fate Therapeutics makes Bob Valamehr president and CEO - MSN

Dec 03, 2024

Dec 03, 2024

Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) PT at $6.75 - MarketBeat

Dec 03, 2024

Dec 03, 2024

Bob Valamehr to succeed CEO Scott Wolchko at Fate - BioCentury

Dec 03, 2024

Nov 30, 2024

Fate Therapeutics appoints new CEO as Wolchko retires By Investing.com - Investing.com Australia

Nov 30, 2024

Nov 29, 2024

Fate Therapeutics Announces Leadership Transition for 2025 - TipRanks

Nov 29, 2024

Nov 29, 2024

Fate Therapeutics Taps Bob Valamehr to Be CEO - MarketWatch

Nov 29, 2024

Nov 29, 2024

Fate Therapeutics Announces Leadership Transition - The Manila Times

Nov 29, 2024

Nov 29, 2024

Fate Therapeutics appoints new CEO as Wolchko retires - Investing.com

Nov 29, 2024

Nov 29, 2024

Fate Therapeutics, Inc. Announces President Changes - Marketscreener.com

Nov 29, 2024

Nov 29, 2024

Vestal Point Capital LP Sells 315,000 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - MarketBeat

Nov 29, 2024

Nov 29, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Sees Large Drop in Short Interest - MarketBeat

Nov 29, 2024

Nov 26, 2024

Fate Therapeutics to Present at Upcoming December Investor Conferences - The Manila Times

Nov 26, 2024

Nov 23, 2024

Fate Therapeutics (NASDAQ:FATE) Given Hold Rating at Needham & Company LLC - Defense World

Nov 23, 2024

Nov 21, 2024

Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook - Investing.com

Nov 21, 2024

Nov 21, 2024

Fate Therapeutics' SWOT analysis: clinical progress boosts stock outlook By Investing.com - Investing.com Canada

Nov 21, 2024

Nov 20, 2024

FATE Presents Encourgaing Data From Lupus Study, Stock Gains - MSN

Nov 20, 2024

Nov 20, 2024

Fate Therapeutics: FT819 Finding Bodes Well For Future Of SLE Treatment Options - Seeking Alpha

Nov 20, 2024

Nov 20, 2024

Fate stock closes 12% higher after soaring 73% on drug data (update) - MSN

Nov 20, 2024

Nov 20, 2024

Bank of America Upgrades Fate Therapeutics (NASDAQ:FATE) to Neutral - Defense World

Nov 20, 2024

Nov 19, 2024

Needham & Company LLC Reaffirms "Hold" Rating for Fate Therapeutics (NASDAQ:FATE) - MarketBeat

Nov 19, 2024

Nov 19, 2024

Fate Thera rockets on early data for FT819 - The Pharma Letter

Nov 19, 2024

Nov 18, 2024

Analyst cites quality-of-life improvements while maintaining Hold on Fate Therapeutics stock - Investing.com

Nov 18, 2024

Nov 18, 2024

BofA upgrades Fate Therapeutics to neutral; target to $3 from $3.50 By Investing.com - Investing.com UK

Nov 18, 2024

Nov 18, 2024

Stock market today: Fate Therapeutics gains 70.79% whereas SiNtx Technologies rose by 38.73% in early trading - Business Upturn

Nov 18, 2024

Nov 18, 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence - The Manila Times

Nov 18, 2024

Nov 18, 2024

Fate Therapeutics Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study with Fludarabine-free Conditioning and FT819 Off-the-shelf, 1XX CAR T-cell Product Candidate at ACR Convergence - GlobeNewswire

Nov 18, 2024

Nov 18, 2024

Fate Therapeutics (FATE) Presents 6-Month Follow-up Data on First Patient Treated in Phase 1 Autoimmunity Study - StreetInsider.com

Nov 18, 2024

Nov 18, 2024

Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed - GlobeNewswire

Nov 18, 2024

Nov 15, 2024

Wedbush Decreases Earnings Estimates for Fate Therapeutics - MarketBeat

Nov 15, 2024

Nov 15, 2024

Fate Therapeutics, Inc. (NASDAQ:FATE) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates - Yahoo Finance

Nov 15, 2024

Nov 14, 2024

Fate Therapeutics stock hits 52-week low at $2.09 By Investing.com - Investing.com Canada

Nov 14, 2024